In vitro and in vivo antileishmanial effects of aloe-emodin on Leishmania major

Abdolhossein Dalimi ； Mahdi Delavari ； Fatemeh Ghaffarifar ； Javid Sadraei

《Journal of Traditional and Complementary Medicine》 5卷2期 (2015/04) Pp. 96-99

https://doi.org/10.1016/j.jtcme.2014.11.004

摘要

Cutaneous leishmaniasis is a common parasitic disease that is endemic in some parts of Iran. The drugs of choice used for leishmaniasis therapy are associated with a risk of recurrence and serious adverse effects. Therefore, finding a safe and effective treatment is of great importance. In the present study, the effect of aloe-emodin on the growth of Leishmania major amastigotes was evaluated under in vitro conditions. In addition, the efficacy of a topical of aloe-emodin ointment was investigated in BALB/c mice with cutaneous leishmanial ulcers. Different concentrations (40 μg/mL, 80 μg/mL, 120 μg/mL, and 160 μg/mL) of aloe-emodin were tested on Leishmania amastigotes twice: 24 hours and 48 hours. The induced apoptosis and necrotic effects of two concentrations (40 μg/mL and 120 μg/mL) of aloe-emodin on promastigotes were investigated by flow cytometry. Under the in vivo condition, aloe-emodin ointment efficacy was evaluated at two concentrations (i.e., 0.1% and 1%). Serum indicator factors of the test and control groups were tested to evaluate the toxic effects of this compound on the liver and kidney. Results showed that aloe-emodin inhibited the growth of Leishmania amastigotes and induced apoptosis in promastigotes. Topical application of aloe-emodin ointment likewise reduced the ulcer size. No significant differences in biochemical analysis were observed between the control and treated groups. In conclusion, aloe-emodin showed antileishmanial effects under in vitro and in vivo conditions and may be used in clinical trials.

關鍵字

aloe-emodin ； apoptosis ； flow cytometry ； in vitro ； in vivo ； Leishmania major

參考文獻

Balasegaram M, Ritmeijer K, Lima MA, et al. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerging Drugs. 2012;17: 493-510.

Romero GA, Vinitius De Farias GM, Gomes PM, de Oliveira M. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L (V) guyanensis in Brazil: clinical findings and diagnostic approach. Clin Infect Dis. 2001;32:1304-1312.

Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Invest Drugs. 2002;3(4).

Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013;368: 524-532.

Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.